Nantahala Capital Management’s Keros Therapeutics KROS Stock Holding History

Nantahala Capital Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-250,000	Closed	-$5.09M	–	165
2025 Q4	$5.09M	Hold	250,000	–	–	0.17%	100
2025 Q3	$3.96M	Hold	250,000	–	–	0.14%	114
2025 Q2	$3.34M	Hold	250,000	–	–	0.13%	107
2025 Q1	$2.55M	Hold	250,000	–	–	0.1%	106
2024 Q4	$3.96M	Buy	+250,000	New	+$13M	0.17%	90
2024 Q1	–	Sell	-11,400	Closed	-$453K	–	136
2023 Q4	$453K	Sell	11,400 -900	-7%	-$28.2K	0.03%	113
2023 Q3	$392K	Hold	12,300	–	–	0.03%	114
2023 Q2	$494K	Hold	12,300	–	–	0.05%	103
2023 Q1	$525K	Sell	12,300 -29,600	-71%	-$1.49M	0.04%	106
2022 Q4	$2.01M	Hold	41,900	–	–	0.13%	77
2022 Q3	$1.58M	Hold	41,900	–	–	0.1%	81
2022 Q2	$1.16M	Hold	41,900	–	–	0.06%	93
2022 Q1	$2.28M	Buy	41,900 +2,200	+6%	+$113K	0.1%	82
2021 Q4	$2.32M	Buy	+39,700	New	+$1.98M	0.08%	102

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Nantahala Capital Management's KROS Position: Q1 2026 in Review

Nantahala Capital Management increased its Keros Therapeutics (KROS) stake by 277% in Q1 2026, buying an estimated $15.4M and bringing the position to 1,360,419 shares worth $15M. The position accounts for 0.55% of the portfolio, ranked #49.

Nantahala Capital Management first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $46.6M in Q4 2021. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Nantahala Capital Management held 1,360,419 shares of Keros Therapeutics worth $15M as of Q1 2026.
Nantahala Capital Management bought 1,000,000 Keros Therapeutics shares in Q1 2026, an estimated $15.4M.
Keros Therapeutics made up 0.55% of Nantahala Capital Management's portfolio in Q1 2026, its #49 holding.
Nantahala Capital Management first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
Nantahala Capital Management's Keros Therapeutics position peaked at $46.6M in Q4 2021.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.